275 related articles for article (PubMed ID: 33150251)
21. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
[TBL] [Abstract][Full Text] [Related]
22. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.
Nishikawa M; Murakumo Y; Imai T; Kawai K; Nagaya M; Funahashi H; Nakao A; Takahashi M
Eur J Hum Genet; 2003 May; 11(5):364-8. PubMed ID: 12734540
[TBL] [Abstract][Full Text] [Related]
23. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
24. RET-deficient mice: an animal model for Hirschsprung's disease and renal agenesis.
Schuchardt A; D'Agati V; Larsson-Blomberg L; Costantini F; Pachnis V
J Intern Med; 1995 Oct; 238(4):327-32. PubMed ID: 7595168
[TBL] [Abstract][Full Text] [Related]
25. Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation.
van Puijenbroek AA; van Weering DH; van den Brink CE; Bos JL; van der Saag PT; de Laat SW; den Hertog J
Oncogene; 1997 Mar; 14(10):1147-57. PubMed ID: 9121763
[TBL] [Abstract][Full Text] [Related]
26. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
Inoue K; Shimotake T; Inoue K; Tokiwa K; Iwai N
J Pediatr Surg; 1999 Oct; 34(10):1552-4. PubMed ID: 10549772
[TBL] [Abstract][Full Text] [Related]
28. The role of the ret proto-oncogene in human disease.
Takahashi M
Nagoya J Med Sci; 1997 Mar; 60(1-2):23-30. PubMed ID: 9212645
[TBL] [Abstract][Full Text] [Related]
29. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
Caron P; Attié T; David D; Amiel J; Brousset F; Roger P; Munnich A; Lyonnet S
J Clin Endocrinol Metab; 1996 Jul; 81(7):2731-3. PubMed ID: 8675603
[TBL] [Abstract][Full Text] [Related]
30. RET and neuroendocrine tumors.
Ichihara M; Murakumo Y; Takahashi M
Cancer Lett; 2004 Feb; 204(2):197-211. PubMed ID: 15013219
[TBL] [Abstract][Full Text] [Related]
31. Ret protooncogene and human-diseases - review.
Takahashi M
Int J Oncol; 1994 Jan; 4(1):81-4. PubMed ID: 21566893
[TBL] [Abstract][Full Text] [Related]
32. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
33. The RET proto-oncogene and cancer.
Donis-Keller H
J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
[TBL] [Abstract][Full Text] [Related]
34. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
36. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
Eng C; Mulligan LM
Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
[TBL] [Abstract][Full Text] [Related]
37. The physical map of the human RET proto-oncogene.
Pasini B; Hofstra RM; Yin L; Bocciardi R; Santamaria G; Grootscholten PM; Ceccherini I; Patrone G; Priolo M; Buys CH
Oncogene; 1995 Nov; 11(9):1737-43. PubMed ID: 7478601
[TBL] [Abstract][Full Text] [Related]
38. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome.
Ponder BA
Cancer Res; 1999 Apr; 59(7 Suppl):1736s-1741s; discussion 1742s. PubMed ID: 10197589
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease.
Borst MJ; VanCamp JM; Peacock ML; Decker RA
Surgery; 1995 Apr; 117(4):386-91. PubMed ID: 7716719
[TBL] [Abstract][Full Text] [Related]
40. Different mutations of the RET gene cause different human tumoral diseases.
Santoro M; Melillo RM; Carlomagno F; Visconti R; De Vita G; Salvatore G; Fusco A; Vecchio G
Biochimie; 1999 Apr; 81(4):397-402. PubMed ID: 10401675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
